



Head and Neck Cancer International Group 2025 Annual Meeting

Penha Campus, University of Algarve, Faro, Portugal

W 12 November 2025:

0900 – 0930: Registration

0930 – 1015: General Assembly [**Closed Session – HNCIG Membership Only**]

- Welcome to Faro
- Chair's Update
- Updates from Committee Chairs

1015 – 1115: Recently Completed HNCIG Projects

- Extranodal Extension Project | *Ahmad Abou-Foul*
- Oligometastasis Survey and Delphi Consensus | *Petr Szturz*
- Trends among Investigators for Suspected Head and Neck Carcinoma of Unknown Primary |
Paul Nankivell

1115 – 1200: Perspectives on Perioperative Immunotherapy in Head and Neck Cancer

- 2025: The Year of Immunotherapy in Operative Head and Neck Cancer | *James Bates*
- Panel Discussion of Perioperative Immunotherapy
 - o Moderator: *Lisa Licitra*
 - o Panellists: *Andreas Dietz, Christopher Holsinger, Yun Gan Tao, Petr Szturz*

Registered Address
Head and Neck Cancer International Group (HNCIG)
4 B rue Emile ZOLA-37000 TOURS-France
Association number W372019315



1200 – 1300: Lunch

1300 – 1345: Unlocking Novel Intratumoral Cancer Therapies Through Pharm and Medtech Synergies

- Speaker: *Hetal Petal*
- Panellists: *Amanda Psyrri, Hisham Mehanna, James Bates,*

1345 – 1430: Update on Ongoing Projects and Proposals

- Post-Operative Radiotherapy in High-risk, Early-stage, Oral Cavity Cancer (PORTHES-OC) | *Pierluigi Bonomo*
- Surrogate Markers for Predicting Response to Neoadjuvant Therapy | *Myrto Moutafi*
- Institutional Survivorship Practice and Intervention: Review and Evaluation in Head and Neck Cancer (INSPIRE; HNCIG-INSPIRE) Study | *Zsuzsanna Iyizoba-Ebozue*

1430 – 1500: Spotlight on Member Organization – Japan Clinical Oncology Group (JCOG)

- Achievements and Ongoing Trials in JCOG-HNCSG | *Naomi Kiyota*
- Innovative JCOG Trials in Head and Neck Oncology | *Yuki Saito*

1500 – 1530: Coffee

1530 – 1630: New Project Proposals

- Readiness of Cooperative Groups to Implement AI in Clinical Trials | *Sujith Baliga*
- NeCTAR: Neoadjuvant Chemotherapy and Immunotherapy (NACI) before Transoral Surgery and Adjuvant Radiotherapy and Chemotherapy (NeCTAR) | *Christian Simon*
- Elective Treatment Discontinuation of Immune Checkpoint Inhibitors in Relapsed/Metastatic Head and Neck Cancer: A Consensus Statement | *Michael Saerens*

1630 – 1730: Oral Abstracts

- Abstract #1: Trial-in-progress: A multicenter, randomized, double blind, phase 2/3 study of ficerafusp alfa (BCA101) or placebo in combination with pembrolizumab for first-line treatment of PD-L1 positive, recurrent or metastatic head and neck squamous cell carcinoma | *Kevin Harrington*
- Abstract #2: Development of treatment decision models for head and neck cancer based on Bayesian networks | *Matthaeus Stoehr*
- Abstract #3: Single Vocal Cord Irradiation (SVCI) vs Whole Laryngeal Radiotherapy in the Treatment of T1aN0 Glottic Cancer: A Prospective Randomized Trial | *Mohamed Elsharief*
- Abstract #4: Trial-in-progress: Smoking Termination in Oncologic Patients with Head and Neck Cancer (STOP-HNC): A multicenter study | *Pierluigi Bonomo*
- Abstract #5: Monocentric prospective study on the feasibility of functional preservation surgery of T3/T4 head and neck cancer – a pirouette around the cricoarytenoid joint | *Todor Popov*

Th 13 November 2025:

0930 – 1200: Creating the International Clinical Trials of the Next Decade

0930 – 1000: Keynote Address

- Experience from European Network of Gynecological Oncology Trials (ENGOT) in Establishing a Successful International Clinical Trials Platform | *Philipp Harter*

1000 – 1030: Results of International Prioritization Process

Pankaj Kumar Panda



1030 – 1045: Coffee Break

1045 – 1200: Brainstorming Sessions: Head and Neck Cancer Clinical Trials of the 2030s

1230: **Registration Open for 10th Trends in Head and Neck Oncology**

Registered Address
Head and Neck Cancer International Group (HNCIG)
4 B rue Emile ZOLA-37000 TOURS-France
Association number W372019315